机译:Rituximab和非缩小脂质体Doxorubicin(R-NPLD R-NPLD)作为前线疗法为80岁或以上的患者侵略性非霍奇金淋巴瘤(NHL NHL)的前线治疗:单中心回顾性研究
Center for the Diagnosis and Treatment of Lymphomas Department of Hematology Transfusion Medicine;
Center for the Diagnosis and Treatment of Lymphomas Department of Hematology Transfusion Medicine;
Center for the Diagnosis and Treatment of Lymphomas Department of Hematology Transfusion Medicine;
Center for the Diagnosis and Treatment of Lymphomas Department of Hematology Transfusion Medicine;
University of Modena and Reggio EmiliaModena Italy;
Department of Medical Oral and Biotechnological Sciences“G. D'Annunzio” UniversityChieti Italy;
Department of Medical Oral and Biotechnological Sciences“G. D'Annunzio” UniversityChieti Italy;
Center for the Diagnosis and Treatment of Lymphomas Department of Hematology Transfusion Medicine;
lymphoma; nonpegylated liposomal doxorubicin; rituximab; very elderly;
机译:Rituximab和非缩小脂质体Doxorubicin(R-NPLD R-NPLD)作为前线疗法为80岁或以上的患者侵略性非霍奇金淋巴瘤(NHL NHL)的前线治疗:单中心回顾性研究
机译:使用或不使用利妥昔单抗的现代化疗(CHOP-14)治疗的老年侵袭性淋巴瘤患者的中枢神经系统事件:德国高级别非霍奇金淋巴瘤研究组(DSHNHL)RICOVER-60试验中治疗患者的分析。
机译:霍奇金淋巴瘤患者自体干细胞移植治疗涉及 - 场放射治疗的预期,多中心研究,伴有侵略性非霍奇金淋巴瘤(allg HDNHL04 / TROG 03.03)
机译:美国非霍奇金淋巴瘤(NHL)商业保险患者发生抑郁或焦虑症的风险:回顾性分析
机译:接受一线治疗的非霍奇金淋巴瘤(NHL)患者的低骨矿物质密度和高骨转换率:一项多中心前瞻性研究的结果
机译:博来霉素,含甲嘧啶和乳尿嘧啶联合非乙二醇化脂质体DOXORUBICIN(MBVD)(≥70岁)或具有霍奇金淋巴瘤的心脏病患者:II期来自FONEAZIONE ITALIANA LINFOMI(FIL)的研究